Table 2.
RTK Inhibitors in Clinical Trials
| Inhibitors | Targets | Study Title | Phase | Status |
|---|---|---|---|---|
| AZD4547 | pan-FGFR | Treatment with AZD4547 for recurrent malignant glioma expressing FGFR-TACC gene fusion. NCT02824133 | 1，2 | Completed |
| Afatinib | EGFR, EGFRvIII, ERBB2, ERBB4 | Safety study of afatinib for brain cancer. NCT02423525 | 1 | Active, not recruiting |
| Bevacizumab* | VEGF-A | Translational study of nivolumab in combination with bevacizumab for recurrent glioblastoma. NCT03890952 | 2 | Recruiting |
| Cediranib | pan-VEGFR | Cediranib maleate and cilengitide in treating patients with progressive or recurrent glioblastoma. NCT00979862 | 1 | Completed |
| Cediranib maleate and olaparib compared to bevacizumab in treating patients with recurrent glioblastoma. NCT02974621 | 2 | Active, not recruiting | ||
| Temozolomide and radiation therapy with or without cediranib maleate in treating patients with newly diagnosed glioblastoma. NCT01062425 | 2 | Active, not recruiting | ||
| Cetuximab | EGFR, EGFRvIII | Intraarterial infusion of erbitux and bevacizumab for relapsed/refractory intracranial glioma in patients under 22. NCT01884740 | 1, 2 | Recruiting |
| Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma. NCT02861898 | 1, 2 | Recruiting | ||
| Crizotinib | MET, ALK | Study to evaluate safety and activity of crizotinib with temozolomide and radiotherapy in newly diagnosed glioblastoma. NCT02270034 | 1 | Active, not recruiting |
| Study of the combination of crizotinib and dasatinib in pediatric research participants with diffuse pontine glioma and high-grade glioma. NCT01644773 | 1 | Completed | ||
| Cabozantinib (XL184) | MET, VEGFR2 | Study of multiple doses and regimens of XL184 (cabozantinib) in subjects with grade IV astrocytic tumors in first or second relapse. NCT01068782 | 2 | Completed |
| Pilot study of cabozantinib for recurrent or progressive high-grade glioma in children. NCT02885324 | 2 | Recruiting | ||
| Dacomitinib | EGFR, ERBB2, HER4 | Safety and efficacy of PF-299804 (dacomitinib), a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation. A Phase II CT.28 NCT01520870 | 2 | Completed |
| PF-00299804 in adult patients with relapsed/recurrent glioblastoma. NCT01112527 | 2 | Completed | ||
| Infigratinib | pan-FGFR | A phase 2 study of BGJ398 in patients with recurrent GBM.29 NCT01975701 | 2 | Completed |
| Infigratinib in recurrent high-grade glioma patients. NCT04424966 | 1 | Recruiting | ||
| INCB28060 | MET | INC280 combined with bevacizumab in patients with glioblastoma multiforme. NCT02386826 | 1 | Active, not recruiting |
| Imatinib | PDGFR, ABL, KIT | Standard chemotherapy vs. chemotherapy guided by cancer stem cell test in recurrent glioblastom. NCT03632135 | 3 | Recruiting |
| mAb806 | EGFR, EGFRvIII | A study of ABT-806 in subjects with advanced solid tumor types.30 NCT01255657 | 1 | Completed |
| Nimotuzumab | EGFR | Nimotuzumab plus radiotherapy with concomitant and adjuvant temozolomide for cerebral glioblastoma.31 NCT03388372 | 2 | Completed |
| Osimertinib | EGFR | 18F-FDG PET and osimertinib in evaluating glucose utilization in patients with EGFR activated recurrent glioblastoma. NCT03732352 | 2 | Active, not recruiting |
| Onartuzumab | MET | A study of onartuzumab in combination with bevacizumab compared to bevacizumab alone or onartuzumab monotherapy in participants with recurrent glioblastoma.32 NCT01632228 | 2 | Completed |
| PLB-1001 | MET | Study of a c-Met inhibitor PLB1001 in patients with PTPRZ1-MET fusion gene positive recurrent high-grade gliomas.23 NCT02978261 | 1 | Completed |
| Sunitinib | VEGFR1,2 PDGFRα, β | HGG-TCP (High grade glioma - tumor concentrations of protein kinase inhibitors). NCT02239952 | Not Applicable | Recruiting |
| A phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma multiforme. NCT03025893 | 2.3 | Recruiting | ||
| Combining sunitinib, temozolomide and radiation to treat patients diagnosed with glioblastoma. NCT02928575 | 2 | Unknown |
Most recent RTK inhibitor clinical trials in GBM were searched at www.Clinicaltrials.gov (2010 to present).
*At time of search, a total of 25 clinical trials are currently recruiting patients in United States.